Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Radical surgery alone for high-risk upper-tract urothelial carcinoma (UTUC) is often inadequate for long-term cancer control. Numerous studies implicate failure presumably attributable to metastatic disease. Therefore, multimodal therapy by way of perioperative chemotherapy is integral to improve cancer outcomes and disease-specific survival. Despite this apparent reality, there is lack of consensus regarding which patients will need additional therapy, optimal timing for delivery of agents, and specific regimens to be utilized. Progress is being made, however, to explore these issues both by extrapolation from the bladder cancer literature as well as studying outcomes from retrospective UTUC series. Prospectively accruing studies for both neoadjuvant and adjuvant chemotherapy will likely mature in the next 5 years thereby providing higher level data to better guide standard of care.

Original languageEnglish (US)
Pages (from-to)543-551
Number of pages9
JournalExpert Review of Anticancer Therapy
Volume14
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

Carcinoma
Drug Therapy
Adjuvant Chemotherapy
Standard of Care
Urinary Bladder Neoplasms
Neoplasms
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

@article{7783d7fafec045788f8cea19853099d8,
title = "Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma",
abstract = "Radical surgery alone for high-risk upper-tract urothelial carcinoma (UTUC) is often inadequate for long-term cancer control. Numerous studies implicate failure presumably attributable to metastatic disease. Therefore, multimodal therapy by way of perioperative chemotherapy is integral to improve cancer outcomes and disease-specific survival. Despite this apparent reality, there is lack of consensus regarding which patients will need additional therapy, optimal timing for delivery of agents, and specific regimens to be utilized. Progress is being made, however, to explore these issues both by extrapolation from the bladder cancer literature as well as studying outcomes from retrospective UTUC series. Prospectively accruing studies for both neoadjuvant and adjuvant chemotherapy will likely mature in the next 5 years thereby providing higher level data to better guide standard of care.",
author = "Lin, {Yu Kuan} and Kaag, {Matthew G.} and Jay Raman",
year = "2014",
month = "1",
day = "1",
doi = "10.1586/14737140.2014.882774",
language = "English (US)",
volume = "14",
pages = "543--551",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "5",

}

Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma. / Lin, Yu Kuan; Kaag, Matthew G.; Raman, Jay.

In: Expert Review of Anticancer Therapy, Vol. 14, No. 5, 01.01.2014, p. 543-551.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Rationale and timing of perioperative chemotherapy for upper-tract urothelial carcinoma

AU - Lin, Yu Kuan

AU - Kaag, Matthew G.

AU - Raman, Jay

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Radical surgery alone for high-risk upper-tract urothelial carcinoma (UTUC) is often inadequate for long-term cancer control. Numerous studies implicate failure presumably attributable to metastatic disease. Therefore, multimodal therapy by way of perioperative chemotherapy is integral to improve cancer outcomes and disease-specific survival. Despite this apparent reality, there is lack of consensus regarding which patients will need additional therapy, optimal timing for delivery of agents, and specific regimens to be utilized. Progress is being made, however, to explore these issues both by extrapolation from the bladder cancer literature as well as studying outcomes from retrospective UTUC series. Prospectively accruing studies for both neoadjuvant and adjuvant chemotherapy will likely mature in the next 5 years thereby providing higher level data to better guide standard of care.

AB - Radical surgery alone for high-risk upper-tract urothelial carcinoma (UTUC) is often inadequate for long-term cancer control. Numerous studies implicate failure presumably attributable to metastatic disease. Therefore, multimodal therapy by way of perioperative chemotherapy is integral to improve cancer outcomes and disease-specific survival. Despite this apparent reality, there is lack of consensus regarding which patients will need additional therapy, optimal timing for delivery of agents, and specific regimens to be utilized. Progress is being made, however, to explore these issues both by extrapolation from the bladder cancer literature as well as studying outcomes from retrospective UTUC series. Prospectively accruing studies for both neoadjuvant and adjuvant chemotherapy will likely mature in the next 5 years thereby providing higher level data to better guide standard of care.

UR - http://www.scopus.com/inward/record.url?scp=84899004037&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899004037&partnerID=8YFLogxK

U2 - 10.1586/14737140.2014.882774

DO - 10.1586/14737140.2014.882774

M3 - Review article

C2 - 24666189

AN - SCOPUS:84899004037

VL - 14

SP - 543

EP - 551

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 5

ER -